IRVINE, Calif., Feb. 2, 2012 /PRNewswire/ -- Syneron Medical Ltd.
(NASDAQ: ELOS), www.syneron.com, the global leader in medical
aesthetic products and technology, announces the launch of
evolastin™– the industry's first energy-based dermal remodeling
procedure that delivers controlled radio frequency energy directly
to the deep dermis to stimulate the skin's natural production of
collagen, elastin and hyaluronic acid in a single treatment.
(Logo:
http://photos.prnewswire.com/prnh/20111107/NY99332LOGO)
A recent randomized and blinded clinical study published by
leading dermatologists in the journal Archives of
Dermatology proved the unique and dramatic impact of evolastin
for patients seeking an alternative to address the loss of tautness
and suppleness most common with age. "It is unprecedented to be
able to achieve results as effective and consistent with a single
energy-based procedure," comments Macrene Alexiades-Armenakas,
M.D., Ph.D, F.A.A.D, board-certified dermatologist in New York City, Assistant Clinical Professor at
Yale University School of Medicine and
lead investigator of evolastin. "In a one-hundred patient
multi-center study conducted using this procedure, we've seen
continual textual, tone or elasticity in addition to volumetric
improvements for up to eighteen months post procedure and patient
satisfaction has been remarkably high and equally consistent."
Unlike traditional energy-based procedures that aim to reach the
dermis through the surface, evolastin positions the entire energy
directly at the base of the dermis using insulated microneedles
that create a unique wound healing response. "evolastin is a
major step forward in the field of facial aesthetics," says
Amy Taub, M.D., board-certified
dermatologist at Advanced Dermatology in Lincolnshire, Illinois and Assistant Clinical
Professor at Northwestern University.
"This procedure gives patients of all skin types results unlike any
other energy-based procedure on the market – it addresses volume
and lifts while improving skin quality and elasticity."
evolastin™ is generally performed under local anesthetic in
about an hour, allowing patients to drive home safely
post-treatment and return to normal activities within 24 hours.
Downtime is minimal with only minor redness, swelling or
bruising for a few days.
"evolastin™ represents our commitment to scientific research and
technological development," said Louis P.
Scafuri, Chief Executive Officer of Syneron Medical.
"The unique results of evolastin coupled with strong clinical
evidence provides a unique minimally invasive solution for our
customers, a revolutionary alternative for their patients and yet
another exciting advancement in our field."
For more information about evolastin or to locate a physician in
your area, visit www.evolastin.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology,
real science and real results – is the leading global aesthetic
device company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables
physicians to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite.
The Company sells its products under two distinct brands,
Syneron and Candela. The Company's aspiration and commitment
to innovation expands Syneron's offering beyond medical device into
the largest in-demand applications in beauty - skin lightening.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
SOURCE Syneron Medical Ltd.